Erythrocytes as a novel drug delivery systems: Current status, challenges and perspectives of medical applications
Eritrociti kao savremeni nosači lekovitih supstanci - trenutni status, izazovi i izgledi za primenu u medicini
Apstrakt
The erythrocytes are the most abundant cellular components ( gt 99%) of blood in humans. Besides their well known physiological functions, they serve as a natural blood compartment participating in biodistribution, metabolism and action of certain drugs. On the other hand, the erythrocytes possess potential carrier capabilities and can be used for the controlled and targeted delivery of various bioactive compounds, including peptides and genetic materials. The erythrocytes feature some unique advantages compared to other delivery systems, such as high biocompatibility, biodegradability, long lifespan, remarkable decrease in concentration fluctuations in steady state in comparison to the conventional methods of drug administration etc. This short review accentuate the most significant experimental results and perspectives of medical applications of novel drug delivery systems based on erythrocytes. .
Eritrociti predstavljaju najzastupljenije ćelijske komponente krvi ( gt 99%) kod ljudi. Pored dobro poznatih fizioloških funkcija koje vrše, oni predstavljaju i prirodne kompartmane krvi koje učestvuju u biodistribuciji, metabolizmu i delovanju određenih lekovitih supstanci. S druge strane, eritrociti poseduju ogroman potencijal kao nosači za kontrolisanu i ciljanu isporuku različitih bioaktivnih jedinjenja, uključujući i peptide i genetički materijal. Produženi životni vek u cirkulaciji, dostupnost, visoka biokompatibilnost i prirodni mehanizmi za bezbednu eliminaciju, kao i značajno smanjenje fluktuacije koncentracije lekovite supstance u plazmi, čine jedinstvene prednosti eritrocita kao nosača lekovitih supstanci u poređenju sa konvencionalnim načinima administracije lekova. Ovaj kratki pregled ističe najznačajnije eksperimentalne rezultate i izglede za primenu eritrocita kao savremenih nosača lekovitih supstanci u medicini. .
Ključne reči:
erythrocytes / carrier / intravascular drug delivery / targeting RES organs / eritrociti / nosači lekovitih supstanci / intravaskularno dejstvo / ciljanje organa RESIzvor:
MD - Medical data, 2012, 4, 3, 287-292Izdavač:
- MOST ART d.o.o., Beograd
Institucija/grupa
Tehnološko-metalurški fakultetTY - JOUR AU - Kostić, Ivana T. AU - Ilić, Vesna Lj. AU - Bugarski, Branko PY - 2012 UR - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/2063 AB - The erythrocytes are the most abundant cellular components ( gt 99%) of blood in humans. Besides their well known physiological functions, they serve as a natural blood compartment participating in biodistribution, metabolism and action of certain drugs. On the other hand, the erythrocytes possess potential carrier capabilities and can be used for the controlled and targeted delivery of various bioactive compounds, including peptides and genetic materials. The erythrocytes feature some unique advantages compared to other delivery systems, such as high biocompatibility, biodegradability, long lifespan, remarkable decrease in concentration fluctuations in steady state in comparison to the conventional methods of drug administration etc. This short review accentuate the most significant experimental results and perspectives of medical applications of novel drug delivery systems based on erythrocytes. . AB - Eritrociti predstavljaju najzastupljenije ćelijske komponente krvi ( gt 99%) kod ljudi. Pored dobro poznatih fizioloških funkcija koje vrše, oni predstavljaju i prirodne kompartmane krvi koje učestvuju u biodistribuciji, metabolizmu i delovanju određenih lekovitih supstanci. S druge strane, eritrociti poseduju ogroman potencijal kao nosači za kontrolisanu i ciljanu isporuku različitih bioaktivnih jedinjenja, uključujući i peptide i genetički materijal. Produženi životni vek u cirkulaciji, dostupnost, visoka biokompatibilnost i prirodni mehanizmi za bezbednu eliminaciju, kao i značajno smanjenje fluktuacije koncentracije lekovite supstance u plazmi, čine jedinstvene prednosti eritrocita kao nosača lekovitih supstanci u poređenju sa konvencionalnim načinima administracije lekova. Ovaj kratki pregled ističe najznačajnije eksperimentalne rezultate i izglede za primenu eritrocita kao savremenih nosača lekovitih supstanci u medicini. . PB - MOST ART d.o.o., Beograd T2 - MD - Medical data T1 - Erythrocytes as a novel drug delivery systems: Current status, challenges and perspectives of medical applications T1 - Eritrociti kao savremeni nosači lekovitih supstanci - trenutni status, izazovi i izgledi za primenu u medicini EP - 292 IS - 3 SP - 287 VL - 4 UR - https://hdl.handle.net/21.15107/rcub_technorep_2063 ER -
@article{ author = "Kostić, Ivana T. and Ilić, Vesna Lj. and Bugarski, Branko", year = "2012", abstract = "The erythrocytes are the most abundant cellular components ( gt 99%) of blood in humans. Besides their well known physiological functions, they serve as a natural blood compartment participating in biodistribution, metabolism and action of certain drugs. On the other hand, the erythrocytes possess potential carrier capabilities and can be used for the controlled and targeted delivery of various bioactive compounds, including peptides and genetic materials. The erythrocytes feature some unique advantages compared to other delivery systems, such as high biocompatibility, biodegradability, long lifespan, remarkable decrease in concentration fluctuations in steady state in comparison to the conventional methods of drug administration etc. This short review accentuate the most significant experimental results and perspectives of medical applications of novel drug delivery systems based on erythrocytes. ., Eritrociti predstavljaju najzastupljenije ćelijske komponente krvi ( gt 99%) kod ljudi. Pored dobro poznatih fizioloških funkcija koje vrše, oni predstavljaju i prirodne kompartmane krvi koje učestvuju u biodistribuciji, metabolizmu i delovanju određenih lekovitih supstanci. S druge strane, eritrociti poseduju ogroman potencijal kao nosači za kontrolisanu i ciljanu isporuku različitih bioaktivnih jedinjenja, uključujući i peptide i genetički materijal. Produženi životni vek u cirkulaciji, dostupnost, visoka biokompatibilnost i prirodni mehanizmi za bezbednu eliminaciju, kao i značajno smanjenje fluktuacije koncentracije lekovite supstance u plazmi, čine jedinstvene prednosti eritrocita kao nosača lekovitih supstanci u poređenju sa konvencionalnim načinima administracije lekova. Ovaj kratki pregled ističe najznačajnije eksperimentalne rezultate i izglede za primenu eritrocita kao savremenih nosača lekovitih supstanci u medicini. .", publisher = "MOST ART d.o.o., Beograd", journal = "MD - Medical data", title = "Erythrocytes as a novel drug delivery systems: Current status, challenges and perspectives of medical applications, Eritrociti kao savremeni nosači lekovitih supstanci - trenutni status, izazovi i izgledi za primenu u medicini", pages = "292-287", number = "3", volume = "4", url = "https://hdl.handle.net/21.15107/rcub_technorep_2063" }
Kostić, I. T., Ilić, V. Lj.,& Bugarski, B.. (2012). Erythrocytes as a novel drug delivery systems: Current status, challenges and perspectives of medical applications. in MD - Medical data MOST ART d.o.o., Beograd., 4(3), 287-292. https://hdl.handle.net/21.15107/rcub_technorep_2063
Kostić IT, Ilić VL, Bugarski B. Erythrocytes as a novel drug delivery systems: Current status, challenges and perspectives of medical applications. in MD - Medical data. 2012;4(3):287-292. https://hdl.handle.net/21.15107/rcub_technorep_2063 .
Kostić, Ivana T., Ilić, Vesna Lj., Bugarski, Branko, "Erythrocytes as a novel drug delivery systems: Current status, challenges and perspectives of medical applications" in MD - Medical data, 4, no. 3 (2012):287-292, https://hdl.handle.net/21.15107/rcub_technorep_2063 .